2-(Biphenyl-2-yloxymethyl)-4,5-dihydro-1H-imidazole

ID: ALA13789

Chembl Id: CHEMBL13789

PubChem CID: 44269124

Max Phase: Preclinical

Molecular Formula: C16H16N2O

Molecular Weight: 252.32

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  c1ccc(-c2ccccc2OCC2=NCCN2)cc1

Standard InChI:  InChI=1S/C16H16N2O/c1-2-6-13(7-3-1)14-8-4-5-9-15(14)19-12-16-17-10-11-18-16/h1-9H,10-12H2,(H,17,18)

Standard InChI Key:  BPRZPBVOIULUSI-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA13789

   2-[(2-phenylphenoxy)methyl]-4,5-dihydro-1H-imidazole

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 252.32

Molecular Weight (Monoisotopic): 252.1263

AlogP: 2.73

#Rotatable Bonds: 4

Polar Surface Area: 33.62

Molecular Species: BASE

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 9.26

CX LogP: 2.53

CX LogD: 0.78

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.91

Np Likeness Score: -0.37

References

1. Baurin N, Vangrevelinghe E, Morin-Allory L, Mérour JY, Renard P, Payard M, Guillaumet G, Marot C..  (2000)  3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology.,  43  (6): [PMID:10737743] [10.1021/jm991124t]

2. Hodson SJ, Bigham EC, Garrison DT, Gobel MJ, Irving PE, Liacos JA, Navas F, Saussy DL, Sherman BW, Speake JD, Bishop MJ..  (2002)  Alpha(1)-adrenoceptor activation: a comparison of 4-(anilinomethyl)imidazoles and 4-(phenoxymethyl)imidazoles to related 2-imidazolines.,  12  (23): [PMID:12419381] [10.1016/s0960-894x(02)00753-9]

3. Gentili F, Bousquet P, Brasili L, Caretto M, Carrieri A, Dontenwill M, Giannella M, Marucci G, Perfumi M, Piergentili A, Quaglia W, Rascente C, Pigini M..  (2002)  Alpha2-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole.,  45  (1): [PMID:11754577] [10.1021/jm0110082]

4. Bishop MJ, Barvian KA, Berman J, Bigham EC, Garrison DT, Gobel MJ, Hodson SJ, Irving PE, Liacos JA, Navas F, Saussy DL, Speake JD..  (2002)  alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines.,  12  (3): [PMID:11814822] [10.1016/s0960-894x(01)00764-8]

5. Nicolotti O, Carotti A, Carrieri A, Pigini M, Gentili F, Brasili L, Giannella M, Quaglia W, Piergentili A, Bousquet P, Dontenwill M.  (2004)  Alpha2-Adrenergic Receptors in Intestinal Epithelial Cells: Mechanisms of Signaling, Role, and Regulation,  13  (3): [10.1007/s00044-004-0023-9]

6. Dosa PI, Amin EA..  (2016)  Tactical Approaches to Interconverting GPCR Agonists and Antagonists.,  59  (3): [PMID:26390077] [10.1021/acs.jmedchem.5b00982]

Source

Source(1):

• Scientific Literature